Reply  by Morasch, Mark D et al.
LETTERS TO THE EDITORRegarding “Safety of gadolinium contrast
angiography in patients with chronic renal
insufficiency”
In a well-performed study, Sam et al (J Vasc Surg 2003;38:
313-8) reported a 9.5% incidence of contrast medium–induced
nephropathy (CIN) when using gadopentetate, a gadolinium-
based contrast medium (Gd-CM), for x-ray angiography in pa-
tients with renal dysfunction. Unfortunately, they stated, “Despite
this, Gd-CM appears to be approximately 20 times safer than
iodinated agents in patients with renal compromise.”
This statement is most likely wrong for two reasons. First, use
of Gd-CM as an alternative to iodinated agents for x-ray diagnostic
angiography and interventions in patients with compromised renal
function has been opposed in a recent review on the physicochem-
ical properties of CM with regard to attenuation and toxicity.1 The
conclusions from this review were as follows:
1. Any comparison regarding nephrotoxic effects between CM
intended for use in x-ray angiography should be made at
concentration and doses resulting in the same diagnostic infor-
mation, ie, equal attenuation of x-rays.
2. No such comparative data have been presented by those who
advocate the use of Gd-CM in azotemic patients.
3. Iodine-based contrast media (I-CM) at a concentration of 63
mg I/mL contain the same number of attenuating iodine
atoms as gadolinium atoms in a 0.5 mol/L Gd-CM solution.
4. I-CM at a concentration of about 60 to 80 mg I/mL seems to
result in the same attenuation as 0.5 mol/L Gd-CM at the
commonly used 70-90 kV used for digital subtraction angiog-
raphy.
5. CM osmolality is a pathogenetic factor in CIN. Commercially
available solutions of iodine-based contrast agents can be di-
luted to isotonic solutions of 60 to 80 mg I/mL, while the
osmolality of 0.5 mol/L gadopentetate is about 7 times that of
plasma, 1960 mOsmol/kg.
6. Using equal-attenuating doses, the general toxicity of various
Gd-CM may be about 6 to 25 times that of I-CM in animal
experiments.
Second, in an experimental unilaterally nephrectomized por-
cine model, about 60 mL of various test solutions were selectively
injected into the balloon-occluded remaining renal artery. Isotonic
solutions of one of the iodine-based contrast media (iohexol), 70
mg I/mL, had no effect on glomerular filtration different from
that of saline injected without ischemia, while the hypertonic
solution of gadopentetate caused almost complete cessation of
renal function.2
In conclusion, the use of hyperosmolar Gd-CM such as gado-
pentetate instead of equal attenuating isotonic solutions of I-CM
should be strongly discouraged for x-ray angiography since equal
attenuating solutions of I-Cm are at least 20 times safer than
gadopentetate!
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Reply
We thank Dr Nyman for his kind interest in our recently
published article and we thank the Journal Editors for this oppor-
tunity to respond to his letter. Dr. Nyman’s work in this area has
certainly helped us to better understand the potential complica-
tions that can arise from the use of all types of contrast media.
We agree with Dr Nyman’s ultimate conclusion that the
intravenous administration of gadopentate (Gd-CM), a strongly
hyperosmolar contrast agent, has the potential to be clinically
nephrotoxic. We would like to take this opportunity to reiterate
the importance of the guidelines for Gd-CM use. The agent should
be administered only for approved indications and in dosages that
are within safe, recommended ranges. We believe that this holds
true for patients both with and without baseline renal insufficiency.
Perhaps some confusion has arisen from our statement that
“gadolinium-based contrast agents appear to be approximately 20
times safer than iodinated agents in patients with renal compro-
mise.” We were referring to its administration alone, in recom-
mended quantities, during magnetic resonance imaging. Like Dr
Nyman, we do not believe that Gd-CM is any safer than iodinated
contrast (I-CM) when used in an off-label manner for x-ray an-
giography. Specifically, Gd-CM is likely no safer than I-CM when
used intra-arterially “as an alternative to iodinated agents for x-ray
diagnostic angiography and interventions” either alone or in com-
bination with I-CM. Perhaps our message has been misunder-
stood. Our intent was to make clear that magnetic resonance
imaging with doses of Gd-CM at 0.02 to 0.03 mmol/kg are safer
than x-ray digital subtraction angiography with iodinated contrast.
We also agree that “contrast media osmolality is a pathogenic
factor in contrast-induced nephropathy” but, to date, no compar-
ative data between I-CM and Gd-CM at equivalent dosages and
concentrations are available upon which one can base a final
conclusion regarding either agent’s relative propensity toward
causing clinically significant renal compromise.
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